Jacob Rotmensch to Bevacizumab
This is a "connection" page, showing publications Jacob Rotmensch has written about Bevacizumab.
Connection Strength
0.048
-
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):22-7.
Score: 0.025
-
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Jun 01; 29(16):2259-65.
Score: 0.023